硫培非格司亭在外周血造血干细胞移植中的应用观察  

Observation on the application of mecapegfilgrastim in peripheral blood hematopoietic stem cell transplantation

作　　者：陈莉[1] 张川莉[1] 陈凤姣[1] 郭彩玲[1] 冷亚美[1] CHEN Li;ZHANG Chuanli;CHEN Fengjiao;GUO Cailing;LENG Yamei(Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China)

机构地区：[1]四川大学华西医院血液科,四川成都610041

出　　处：《西部医学》2022年第7期1046-1049,1055,共5页Medical Journal of West China

基　　金：四川省卫生厅科研项目(150115)。

摘　　要：目的 探讨硫培非格司亭注射液和重组人粒细胞刺激因子(rhG-CSF)注射液在外周血造血干细胞移植术后对刺激粒细胞生长的有效性及经济效应。方法 回顾性分析2018年4月~2019年4月我院收治的行外周造血干细胞移植术的患者70例,按照随机数字表法分为硫培非格司亭组和重组人粒细胞刺激因子组(rhG-CSF组),每组35例。在自体造血干细胞移植术后1 d或异基因造血干细胞移植术后5 d分别予硫培非格司亭注射液和重组人粒细胞刺激因子皮下注射。对比两组患者粒细胞生长速度,比较两组患者治疗期间的不良反应发生率及经济效应。结果 硫培非格司亭组和rhG-CSF组在粒细胞平均植活天数比较中无统计学意义(P>0.05);药物相关并发症骨关节肌肉疼痛、发热、皮损的发生率比较差异无统计学意义(P>0.05),但rhG-CSF组皮损例数多于硫培非格司亭组;粒细胞上升期骨关节肌肉疼痛发生率差异无统计学意义(P>0.05)。注射次数比较:硫培非格司亭组患者只需注射1次,rhG-CSF组患者需注射8~17次,平均注射14次。经济费用比较:硫培非格司亭组费用为3080元,rhG-CSF组平均费用为2876元。结论 硫培非格司亭注射液在外周血造血干细胞移植术后对粒细胞促升有效,其注射简单、方便,病员依从性及舒适度相较更高,可在外周血造血干细胞移植中推广应用。Objective To investigate the efficacy and economic effect of mecapegfilgrastim injection and recombinant human granulocyte stimulating factor injection in stimulating granulocyte growth after peripheral blood hematopoietic stem cell transplantation.Methods Retrospective analysis was performed on 70 patients who received peripheral hematopoietic stem cell transplantation from April 2018 to April 2019,and they were divided into mecapegfilgrastim group and recombinant human granulose-stimulating factor group.On the first day after autologous HSCT or on the fifth day after allogeneic HSCT,subcutaneous injections of mecapegfilgrastim injection and recombinant human granulocyte stimulating factor were given respectively.The rate of granulocyte growth was compared between the two groups,and the incidence of adverse reactions and economic effects were compared between the two groups during treatment.Results There was no significant difference in the mean granulocyte survival days between the two groups between mecapegfilgrastim group and recombinant human granulocyte stimulating factor group(P>0.05);In terms of drug-related complications,the incidence of pain,fever and skin lesions was not statistically significant(P>0.05),but the number of skin lesions in rhG-CSF group was higher than that in mecapegfilgrastim group.There was no statistical significance in the incidence of osteoarticular muscle pain(P>0.05).In terms of the injection frequency,patients in the mecapegfilgrastim group received only one injection,and patients in the recombinant human granuloplastin group received 8-17 injections(mean 14 injections).In terms of economic cost,the average cost of mecapegfilgrastim group was 3080 yuan,and the average cost of recombinant human granulocyte stimulating factor group was 2876 yuan.Conclusion There was no significant difference between the two groups in the effect of stimulating granulocyte growth after hematopoietic stem cell transplantation and the occurrence of pain during granulocyte ascension stage.In terms of c

关 键 词：硫培非格司亭 重组人粒细胞刺激因子 外周血造血干细胞移植术 中性粒细胞减少 

分 类 号：R457.7[医药卫生—治疗学]